(Press-News.org) The CORRECT study, published ahead of print online today in The Lancet Oncology, is one of the largest trials to date comparing data provided by liquid versus tissue biopsy in metastatic colorectal cancer patients.
According to the study, liquid biopsy (BEAMing technology) could become an essential tool for analyzing tumor genotypes in real time, and identifying significant mutations that occur during the course of disease and are not detected by tissue biopsy.
The results of the phase III study, co-directed by Josep Tabernero, Head of the Vall d'Hebron University Hospital´s Medical Oncology Department and Director of the Vall d'Hebron Institute of Oncology (VHIO), also show that the use of regorafenib, an inhibitor of diverse proteins implicated in tumor evolution, shows modest clinical benefits in patients refractory to standard treatment for this type of cancer.
Liquid biopsy can be performed much more quickly and much less invasively (as a simple blood extraction) than tissue biopsy, and is highly sensitive to RAS biomarkers (KRAS and NRAS) in metastatic colorectal cancer. Some 55% of patients with this type of cancer have tumors harboring RAS mutations.
Barcelona, 14 July 2015. An international, randomized, phase III study has analyzed the DNA of 503 patients with metastatic colorectal cancer by liquid biopsy (BEAMing platform) to detect KRAS, PIK3CA and BRAF gene mutations in tumors. These patients, who had previously received different treatment lines, were administered either the multi-kinase inhibitor regorafenib or placebo. Regorafenib is an inhibitor of several proteins involved in oncogenesis and tumor angiogenesis.
The results of the trial were twofold: liquid biopsy effectively unmasked different tumor-related mutations. More specifically, in a subgroup of 41 patients who had previously received anti-EGFR therapy, it was revealed that they had acquired KRAS mutations during the course of their disease. Such accurate information is difficult to obtain using tissue biopsy which could, in the absence of this data, lead to a selection of therapy which may not be the most appropriate for these patients. Moreover, the study concludes that regorafenib is effective in patients with KRAS and PIK3CA mutations.
"This is the first large clinical trial to compare liquid versus conventional tissue biopsy data, and the results show the former (BEAMing technology) obtain more data on tumor mutation throughout the course of the disease, enabling us to better target therapy to the specificities of patient´s tumor; this could have a considerable impact on clinical practice, as novel applications of this technology could be further investigated and developed", says Josep Tabernero, Head of the Medical Oncology Department of Hospital Universitario Vall d'Hebron, Director of VHIO, and Co-Director of the study.
The majority of clinical studies published on the use of DNA in blood to determine tumor genotype, have only enrolled a relatively small number of patients which limits the significance of the findings as well as the ability to research possible correlations between genotype and clinical outcome. Furthermore, most studies evaluated a single gene (such as KRAS) and used technologies that are not commercially available. The importance of the CORRECT trial is that it involved a large number of patients, providing correlative analyses that showed clinical benefits of regorafenib in all the subgroups in which mutations had been identified.
Liquid biopsy: facilitating analysis of mutations and improved selection of targeted therapies tailored to the specifities of each patient´s tumor
Tumor genotype plays an important role in drug resistance in patients with metastatic colorectal cancer, but the genotype obtained at diagnosis can vary after different treatment lines. Therefore, DNA analysis using liquid biopsy has clear advantages over DNA analysis with tissue biopsy and is rapidly gaining importance and momentum in the oncology field.
Liquid biopsy, also known as a blood-based biomarker test, is a fast, simple method for detecting RAS (KRAS and NAS) mutation status in tumors, as it only requires a blood test rather than a tissue biopsy or surgical procedure. Further, it also provides mutation status results in a matter of days, helping to determine the most specific, targeted treatment in each case. It represents one more important step in realizing the true promise of precision medicine in oncology - the main focus behind research at VHIO which aims to both advance and deliver targeted therapies tailored to the particularities of each tumor for an increasing number of patients.
Although there are still some important questions that will need to be resolved concerning liquid biopsy, for example, the possibility that not all tumors release enough DNA into the blood for it to be detected, as well as the difficulty of assigning a particular genotype for each particular tumor in patients with multiple metastases, the CORRECT study shows that liquid biopsy could become an essential tool in clinical practice.
INFORMATION:
About colorectal cancer
Colorectal cancer is the second most common cancer in the world, with an estimated incidence rate of more than 1.36 million new cases per year. Around 694,000 people die from colorectal cancer every year, accounting for 8.5% of all cancer deaths, ranking as the fourth most common cause of death from cancer. Approximately 55% of all colorectal cancer cases are diagnosed in the world's developed regions, and the incidence and mortality rates are considerably higher among men than in women.
Funeral directors, who prepare bodies for burial, may be at heightened risk of the neurodegenerative disease amyotrophic lateral sclerosis, or ALS for short, as a result of the formaldehyde used in embalming fluid, suggests research published online in the Journal of Neurology Neurosurgery & Psychiatry.
ALS, also known as Lou Gehrig's disease, was the subject of last year's ice bucket challenge. It is progressive, causing muscle weakness, paralysis, and eventually respiratory failure and death. There is no cure for the condition, which is thought to affect 450,000 people ...
One in four dogs competing in the world's largest canine show (Crufts) is overweight, despite the perception that entrants are supposed to represent ideal specimens of their breed, reveals research published online in Veterinary Record.
The widespread dissemination of show dog images online may be 'normalising' obesity in dogs, now recognised to be a common canine disorder, say the researchers.
As in people, obesity in dogs has been linked to orthopaedic problems, diabetes, respiratory disease, and certain types of cancer. It also affects both the quality and length ...
One in four dogs competing at Crufts is overweight, researchers at the University of Liverpool have found.
The competition is the largest show of its kind in the world, showcasing the best physical and behavioural qualities in a variety of canine breeds. Research, published in the Veterinary Record, however, reveals that up to 26% of some of the best show dogs, such as pugs, Basset hounds, and Labrador retrievers, are actually overweight.
The team studied more than a 1,000 images of 28 dog breeds that had been placed between first and fifth in their class during ...
1. Community Preventive Services Task Force recommends diet and exercise interventions to prevent diabetes
Evidence shows combined diet and exercise promotion programs are effective and cost-effective for preventing type 2 diabetes in at-risk patients
Free content
Clinical guideline: http://www.annals.org/article.aspx?doi=10.7326/M15-1029
Evidence review: http://www.annals.org/article.aspx?doi=10.7326/M15-0452
Economic evidence review: http://www.annals.org/article.aspx?doi=10.7326/M15-0469
Editorial: http://www.annals.org/article.aspx?doi=10.7326/M15-1563
URLs ...
PHILADELPHIA -Patients over 50 with ulcerative colitis (UC), a chronic disease of the colon, who undergo surgery to treat their condition live longer than those who are treated with medications, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. The results are published this week in Annals of Internal Medicine.
"Ulcerative colitis is a chronic disease that most physicians opt to treat with medications, as opposed to surgery," said the study's lead author Meenakshi Bewtra, MD, PhD, MPH, assistant professor of Medicine and ...
In preliminary research, a small number of occult (hidden) malignancies were subsequently diagnosed among pregnant women whose noninvasive prenatal testing results showed chromosomal abnormalities but the fetal karyotype was subsequently shown to be normal, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the 19th International Conference on Prenatal Diagnosis and Therapy in Washington, D.C.
Understanding the relationship between aneuploidy detection (an abnormal number of chromosomes) on noninvasive prenatal testing ...
Boulder, Colo., USA - Super-eruptions are not the only type of eruption to be considered when evaluating hazards at volcanoes with protracted eruption histories, such as the Yellowstone (Wyoming), Long Valley (California), and Valles (New Mexico) calderas. There have been more than 23 effusive eruptions of rhyolite lava at Yellowstone since the last caldera-forming eruption ~640,000 years ago, all of similar or greater magnitude than the largest volcanic eruptions of the 20th century.
This study by Christy B. Till and colleagues is innovative because it is the first ...
DURHAM, N.C. - Practically everyone gets fatter as they get older, but some people can blame their genes for the extra padding. Researchers have shown that two different mutations in a gene called ankyrin-B cause cells to suck up glucose faster than normal, fattening them up and eventually triggering the type of diabetes linked to obesity.
The more severe of the two mutations, called R1788W, is carried by nearly one million Americans. The milder mutation, known as L1622I, is shared by seven percent of the African American population and is about as common as the trait ...
CHICAGO-- The use of 3D printers has the potential to revolutionize the way food is manufactured within the next 10 to 20 years, impacting everything from how military personnel get food on the battlefield to how long it takes to get a meal from the computer to your table, according to a July 12th symposium at IFT15: Where Science Feeds Innovation hosted by the Institute of Food Technologists (IFT) in Chicago.
The price of 3D printers has been steadily declining, from more than $500,000 in the 1980s to less than $1,000 today for a personal-sized device, making them increasingly ...
CHICAGO-- Dr. Mark J. Post is confident his recipe for his $300,000 cultured hamburger will not only come down in price but someday make it to market, according to a July 12th presentation at IFT15: Where Science Feeds Innovation hosted by the Institute of Food Technologists (IFT) in Chicago.
"It's realistic that we can do this," said Post, chair of the department of physiology and professor of vascular physiology and tissue engineering, Maastricht University, The Netherlands, who is refining what he already sees as a patty consistent in look, texture and color to a traditional ...
